Milk-alkali syndrome

Milk-alkali syndrome
ICD-9	275.42
DiseasesDB	8215
MedlinePlus	000332
eMedicine	med/1477

WikiDoc Resources for Milk-alkali syndrome
Articles
Most recent articles on Milk-alkali syndrome Most cited articles on Milk-alkali syndrome Review articles on Milk-alkali syndrome Articles on Milk-alkali syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Milk-alkali syndrome Images of Milk-alkali syndrome Photos of Milk-alkali syndrome Podcasts & MP3s on Milk-alkali syndrome Videos on Milk-alkali syndrome
Evidence Based Medicine
Cochrane Collaboration on Milk-alkali syndrome Bandolier on Milk-alkali syndrome TRIP on Milk-alkali syndrome
Clinical Trials
Ongoing Trials on Milk-alkali syndrome at Clinical Trials.gov Trial results on Milk-alkali syndrome Clinical Trials on Milk-alkali syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Milk-alkali syndrome NICE Guidance on Milk-alkali syndrome NHS PRODIGY Guidance FDA on Milk-alkali syndrome CDC on Milk-alkali syndrome
Books
Books on Milk-alkali syndrome
News
Milk-alkali syndrome in the news Be alerted to news on Milk-alkali syndrome News trends on Milk-alkali syndrome
Commentary
Blogs on Milk-alkali syndrome
Definitions
Definitions of Milk-alkali syndrome
Patient Resources / Community
Patient resources on Milk-alkali syndrome Discussion groups on Milk-alkali syndrome Patient Handouts on Milk-alkali syndrome Directions to Hospitals Treating Milk-alkali syndrome Risk calculators and risk factors for Milk-alkali syndrome
Healthcare Provider Resources
Symptoms of Milk-alkali syndrome Causes & Risk Factors for Milk-alkali syndrome Diagnostic studies for Milk-alkali syndrome Treatment of Milk-alkali syndrome
Continuing Medical Education (CME)
CME Programs on Milk-alkali syndrome
International
Milk-alkali syndrome en Espanol Milk-alkali syndrome en Francais
Business
Milk-alkali syndrome in the Marketplace Patents on Milk-alkali syndrome
Experimental / Informatics
List of terms related to Milk-alkali syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Milk-alkali syndrome, also called Burnett's syndrome in honour of the American physician who first described it, is characterized by hypercalcemia caused by repeated ingestion of calcium and absorbable alkali (such as calcium carbonate, or milk and sodium bicarbonate). If untreated, milk-alkali syndrome may lead to metastatic calcification and renal failure.

It was most common in the early 20th century, but there has been a recent increase in the number of cases reported.

Pathophysiology

The name "milk-alkali syndrome" derives from when patients would take in excessive amounts of milk and antacids to control their dyspepsia, leading to overingestion of two key ingredients that lead to the disorder, excess calcium and excess base. Ingesting over two grams of elemental calcium per day produces this disorder in susceptible individuals. Gastrointestinal absorption of such a large amount of calcium leads to hypercalcemia. This inhibits parathyroid hormone secretion by the parathyroid gland and may also lead to diabetes insipidus. The body's attempt to rid itself of the excess base in the urine may cause bicarbonaturia and subsequent hypovolemia due to transport of sodium ions to accompany the bicarbonate.

Hypovolemia may increase the reabsorption of calcium and bicarbonate in the proximal convoluted tubules of the kidney. Elevated bicarbonate levels in the blood raises the pH, producing an alkalemia. In this state, excess bicarbonate eventually begins to reach the distal convoluted tubule, leading to sodium retention in the lumen, an effect similar to the action of thiazide diuretics, hence increasing lumen positivity and driving calcium through the passive calcium channels to bind intracellular calbindin. Finally, because of the decreased intracellular sodium, there is an increased driving force for the basolateral Na+/Ca++ antiporter, thus facilitating calcium reabsorption. Basically, hypovolemia is the culprit that prevents correction of the hypercalcemia.

The understanding of this mechanism led to the development of a simple yet elegant treatment for hypercalcemia. The first and most important step is intravenous infusion of normal saline to restore the intravascular volume, which reverses the calcium and bicarbonate retention in the PCT. Then a loop diuretic is used, but only after the volume replacement is complete, otherwise volume contraction would result, which would further exacerbate the hypercalcemia. The loop diuretics inhibit the Na-K-2Cl symporter and hence eliminate passive diffusion of potassium into the lumen via the ROMK channel. This effectively removes the net positive charge from the lumen, one of the main driving forces for calcium reabsorption via the paracellular pathway. In addition, loop diuretics increase the flow of luminal contents, which helps flush the calcium to the distal nephron.

Clinical

Effects due to hypercalcemia may be remembered by bones, stones, groans and psychiatric overtones. This means an increased risk of kidney stones, bone fractures, anorexia, vomiting, constipation and a host of psychiatric effects, including weakness, fatigue and altered mental status. Thus, a level of serum calcium must be obtained, but a full workup must include total/ionized calcium, albumin, phosphate, PTH, PTHrP, vitamin D and TSH. In addition, evaluation of hypercalcemia must include an ECG, which may show a short QT interval.

Eponym

It is named for Charles Hoyt Burnett.

External links

• eMedicine.com - Milk-Alkali Syndrome ([3])

de:Burnett-Syndrom